Episode Details
Back to Episodes
LIVN: The Medtech Monopoly Hiding a 73% Valuation Gap
Description
LIVN stock analysis: 16% EPS beat signals +73% upside β full valuation deep dive
π Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends
In this deep dive, we break down LivaNova PLC (LIVN) and its strong Q3 2026 earnings surprise, driven by double-digit growth in cardiopulmonary consumables and VNS therapy for epilepsy. With shares trading around 20x forward earnings and constant-currency revenue growing 10% YoY, the key question for investors is whether its $155.88 probability-weighted price target outweighs legacy litigation and expansion execution risks. Hereβs everything you need to know before making a decision on LIVN.
π― SECTIONS:
β’ Executive Summary & Medtech Business Overview
β’ Cardiopulmonary & Neuromodulation Growth Drivers
β’ Economic Moat, Switching Costs & IP Analysis
β’ Total Addressable Market (TAM) Opportunity
β’ Q3 2026 Earnings Results & Guidance Boost
β’ Wall Street Analyst Ratings & Valuation Framework
β’ Key Execution, Regulatory & Legal Risk Factors
β’ 5-Year Scenario Analysis & Probability-Weighted Price Target
β’ Qualitative Scorecard & Management Alignment
β’ Final Investment Thesis & Technical Analysis Outlook
All the research behind this video was created using Flash by StockSentinel.ai, giving you FREE access to investment research reports on any public company in the world. Free features include:
β
Explainer Videos
β
Audio Podcasts
β
Detailed Reports
β
Investor Presentations with full qualitative and quantitative analysis
Subscribers also unlock exclusive features including Best Ideas Now (6 highest-conviction picks every Saturday), Portfolio Watch, Insider IQ alerts on significant global insider buying activity, and the Flash Community.
Subscribe + π to never miss a stock report
DISCLAIMER: This content is for informational and educational purposes only and is not investment advice. Opinions are personal and may change. Do your own research or consult a licensed professional. StockSentinel.ai is under no obligation to update this information.
#StockAnalysis #StockMarket #Investing #Stocks #ValueInvesting #StockResearch #InvestmentAnalysis #FinancialAnalysis #LIVN #LivaNova #LIVNStock #HealthcareStocks #MedTech #DeepDive #FundamentalAnalysis #ValuationAnalysis #StockPicks #WallStreet #NASDAQ